Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group

British Journal of Cancer

Volumn 74, Issue 6, 1996, Pages 961-963

  Van Meerbeeck, J ^a   Debruyne, C ^b   Van Zandwijk, N ^c   Postmus, P E ^d   Pennucci, M C ^e   Van Breukelen, F ^f   Galdermans, D ^g   Groen, H ^h   Pinson, P ⁱ   Van Glabbeke, M ^b   Van Marck, E ^a   Giaccone, G ^d  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b EORTC DATA CENTER   (Belgium)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF GENOA   (Italy)

^f Infection and Immunology   (Netherlands)

^g MIDDELHEIM HOSPITAL   (Belgium)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Malignant pleural mesothelioma; Paclitaxel

Indexed keywords

ANTIHISTAMINIC AGENT; CIMETIDINE; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG HYPERSENSITIVITY; FEMALE; FEVER; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PREMEDICATION; PRIORITY JOURNAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 10144263925     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.465     Document Type: Article

References (25)

1. BALL DL AND CRUICKSHANK DG. (1990). The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am. J. Clin. Oncol., 13, 4-9.
2. BOUTIN C, REY F, GOUVERNET I, VIALLET JR, ASTOUL P AND LEDORAY V. (1993). Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Cancer, 72, 394-404.
3. VAN BREUKELEN JF, MATTSON K, GIACCONE G, VAN ZANDWIJK N, PLANTEYDT HT, KIRKPATRICK A AND DALESIO O. (1991). Mitoxantrone in malignant pleural mesothelioma: a study of the EORTC Lung Cancer Cooperative Group. Eur. J. Cancer, 27, 1627-1629.
4. CALAVREZOS A, KOSHEL G, HUSSELMANN H, TAYLESSANI A, HEILMAN HP, FABEL H, SCHMOLL HJ, DIETRICH H AND HAIN E. (1988). Malignant mesothelioma of the pleura. Klin. Wochenschr, 66, 607-613.
5. DE KLERK NH AND ARMSTRONG BK. (1992). The epidemiology of asbestos and mesothelioma. In Malignant Mesothelioma, Henderson DW, Shelkin KB, Langlois SLP and Withaker D. (eds), pp. 223-243. Hemisphere Publishing Cooperation: New York.
6. EORTC. (1994). Evaluation criteria, scoring scales and instruments. In EORTC: A Practical Guide to EORTC Studies. Vantongelen K. (ed.) pp. 119-131. EORTC: Brussels.
7. GUPTA RS. (1993). Taxol resistant mutants of Chinese hamster ovary cells: genetic, biochemical and cross-resistance studies. J. Cell Physiol., 114, 137-144.
8. HENDERSON DW, WHITHAKER D AND SHELKIN KB. (1992). The differential diagnosis of malignant mesothelioma: a practical approach to diagnosis during life. In Malignant Mesothelioma, Henderson DW, Shelkin KB, Langlois SLP and Withaker D. (eds), pp. 183-1940. Hemisphere Publishing Cooperation: New York.
9. KAPLAN GL AND MEIER P. (1958). Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc., 53, 457-481.
10. KRARUF-HANSEN A AND HANSEN HH. (1991). Chemotherapy in malignant mesothelioma: a review. Cancer Chemother. Pharmacol., 28, 319-330.
11. KRARUF-HANSEN A. (1994). Phase II trials of malignant mesothelioma: a commentary and update. Lung Cancer, 11, 305-308.
12. LANGLOIS SLP AND HENDERSON DW. (1992). Radiological investigation of mesothelioma. In Malignant Mesothelioma, Henderson DW, Shelkin KB, Langlois SLP and Withaker D. (eds), pp. 259-276. Hemisphere Publishing Cooperation: New York.
13. MATTSON K, GIACCONE G, KIRKPATRICK A, EVRARD D, PLANTEYDT HT AND VAN ZANDWIJK N. (1992). Epirubicin in malignant mesothelioma: a phase II study of the EORTC-LCCG. J. Clin. Oncol., 10, 824-828.
14. VAN MEERBEECK JP. (1994). Prognostic factors in malignant mesothelioma: where do we go from here? Eur. Respir. J., 6, 1029-1031.
15. MUSK AW, BOWMAN RV AND CHRISTMAS TI (1992). Management of malignant mesothelioma. In Malignant Mesothelioma, Henderson DW, Shelkin KB, Langlois SLP and Withaker D. (eds), pp. 292-299. Hemisphere Publishing Cooperation: New York.
16. PISANI RJ. (1988). Malignant mesothelioma of the pleura. Mayo Clin. Proc., 63, 1234-1244.
17. RAMAEL M, BUYSSE C, VAN DEN BOSSCHE J, SEGERS K AND VAN MARK E. (1992). Immunoreactivity for P-170 glycoprotein in malignant mesothelioma and non-neoplastic mesothelium with the JSB-1 monoclonal antibody. J. Pathol., 167, 5-8.
18. ROWINSKY EK AND DONEHOVVER RC. (1995). Paclitaxel (Taxol). N. Engl. J. Med., 332, 1004-1014.
19. ROWINSKY EK, EISENHAUER EA, CHAUDHRY V, ARBUCK SG AND DONEHOWER RC. (1993). Clinical toxicities encountered with Paclitaxel (Taxol). Semin. Oncol., 20, 1-15.
20. RUSH VW, PIANTADOSI S AND HOLMES EC. (1991). The role of extrapleural pneumonectomy in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg., 102, 1-9.
21. SCHILLER JH, STORER B, TUTSCH K, ARZOOMANIAN R, ALBERTI D, FEIERABEND C AND SPRIGGS D. (1994). Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J. Clin. Oncol., 12, 241-248.
22. SIMON R. (1989). Optimal two-stage design for phase II clinical trials. Controlled Clin. Trials, 10, 1-10.
23. UICC. (1992). International Union against Cancer: TNM atlas, 3rd edn. pp. 152-156. Springer: Berlin.
24. VOGELSANG NJ. (1992). Malignant mesothelioma: diagnostic and management strategies for 1992. Semin. Oncol., 19 (suppl. 11), 64-71.
25. VOGELSANG NJ, HERNDON J, CLAMON GH, MAUER AM, COOPER MR AND GREEN MR. (1994). Paclitaxel (Taxol) for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B (CALGB 9234). Proc. Am. Soc. Clin. Oncol., 13, 405.